FY2023 EPS Estimates for Ocuphire Pharma, Inc. (NASDAQ:OCUP) Raised by Analyst

Posted by on Apr 6th, 2023

Ocuphire Pharma, Inc. (NASDAQ:OCUP – Get Rating) – Investment analysts at Cantor Fitzgerald raised their FY2023 earnings per share estimates for shares of Ocuphire Pharma in a research note issued to investors on Monday, April 3rd. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings of $0.17 per share for the year, up from their previous forecast of $0.13. The consensus estimate for Ocuphire Pharma’s current full-year earnings is ($0.26) per share.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Ocuphire Pharma in a research note on Friday, March 31st.

Ocuphire Pharma Stock Down 9.2 %

NASDAQ:OCUP opened at $4.72 on Wednesday. The company has a market capitalization of $98.78 million, a PE ratio of 6.21 and a beta of 0.30. Ocuphire Pharma has a 52-week low of $1.78 and a 52-week high of $5.43. The stock has a fifty day simple moving average of $3.64 and a 200-day simple moving average of $3.06.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Kestra Private Wealth Services LLC acquired a new position in Ocuphire Pharma in the 1st quarter valued at about $32,000. Lincoln National Corp acquired a new position in Ocuphire Pharma in the 4th quarter valued at about $41,000. Bedel Financial Consulting Inc. acquired a new position in Ocuphire Pharma in the 3rd quarter valued at about $31,000. Bank of Montreal Can acquired a new position in Ocuphire Pharma in the 1st quarter valued at about $68,000. Finally, Legato Capital Management LLC acquired a new position in Ocuphire Pharma in the 4th quarter valued at about $58,000. Institutional investors and hedge funds own 13.59% of the company’s stock.

Ocuphire Pharma Company Profile

(Get Rating)

Ocuphire Pharma, Inc engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Featured Stories

Receive News & Ratings for Ocuphire Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocuphire Pharma and related companies with MarketBeat.com's FREE daily email newsletter.